Alirocumab-associated unilateral posterior uveitis
Inegbedion, Ehinomen Sarah Azzopardi, Matthew Inessa, Tracey
Inegbedion, Ehinomen Sarah
Azzopardi, Matthew
Inessa, Tracey
Citations
Altmetric:
Affiliation
Sandwell and West Birmingham NHS Trust; Barts Health NHS Trust
Other Contributors
Publication date
2024-01-24
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
A man in his mid-40s who had been recently started on alirocumab (a human monoclonal antibody which inhibits proprotein convertase subtilisin/kexin type 9) due to his strong familial cardiovascular risk and refractory hypercholesterolaemia presented with a few-hour history of acute-onset left-sided blurred vision. The best-corrected visual acuities were 6/6 bilaterally and slit-lamp examination was normal. However, optical coherence tomography revealed serous subretinal fluid in the left macula. Optos ultra-widefield retinal imaging and fundus autofluorescence, along with a set of blood tests, did not reveal any alternative causes. A diagnosis of alirocumab-associated uveitis was diagnosed. Alirocumab was stopped and he was followed up in uveitis clinic. Within 4 months following alirocumab cessation, the subretinal fluid resolved completely. This case report emphasises the importance of early multidisciplinary team involvement, since novel therapeutic agents can have unexpected adverse events.
Citation
Inegbedion ES, Azzopardi M, Inessa T, Chong YJ. Alirocumab-associated unilateral posterior uveitis. BMJ Case Rep. 2024 Jan 24;17(1):e258183. doi: 10.1136/bcr-2023-258183
Type
Article